Fas Ligand Gene Therapy for Vascular Intimal Hyperplasia

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|4|1|33-39

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.4, Iss.1, 2004-01, pp. : 33-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer

By  

Current Gene Therapy, Vol. 1, Iss. 1, 2001-05 ,pp. : 123-136

Bentham Science Publishers

Access to resources Recommend Favorite

Considering Fas ligand as a target for therapy

By Linkermann Andreas   Qian Jing   Lettau Marcus   Kabelitz Dieter   Janssen Ottmar  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 1, 2005-02 ,pp. : 119-134

Informa Healthcare

Access to resources Recommend Favorite

Intimal Hyperplasia in Murine Models

By  

Current Drug Targets, Vol. 9, Iss. 3, 2008-03 ,pp. : 251-260

Bentham Science Publishers

Access to resources Recommend Favorite

Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet

By Fukuyama J.   Ichikawa K.   Hamano S.   Shibata N.  

European Journal of Pharmacology, Vol. 318, Iss. 2, 1996-12 ,pp. : 327-332

Elsevier

Access to resources Recommend Favorite

IL-10 reduces postinjury intimal hyperplasia

By  

Inpharma, Vol. 1, Iss. 1235, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite